BIO, QLS Advisors, and Informa Pharma Intelligence have released a new report on clinical development success rates covering 2011-2020. The report includes comparisons of success rates across indications and modalities, regulatory factors, and predictive factors driving successes and failures in drug development. This new data will help shape risk profiles and valuation metrics across investment and pharma R&D portfolios.
- BlackRock and QLS Advisors Partner Through BlackRock Systematic to Invest in Biomedical Innovation
- BIO, QLS, and Informa Pharma Intelligence have released a new report on clinical development success rates covering 2011-2020
- Informa Pharma Intelligence and QLS Partner to Pilot Predictive Analysis Tool for Clinical Trials